Sun Young Rha
A5024676627- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Renal and related cancers
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Genetic factors in colorectal cancer
- Helicobacter pylori-related gastroenterology studies
- Bladder and Urothelial Cancer Treatments
- Esophageal Cancer Research and Treatment
- Epigenetics and DNA Methylation
Yonsei University
2016-2025
Yonsei University Health System
2016-2025
Severance Hospital
2013-2025
University Health System
2010-2024
Korea Institute of Brain Science
2003-2023
University of Lucerne
2010-2023
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2007-2020
Luzerner Kantonsspital
2011-2020
National Research Foundation of Korea
2017
Chungnam National University
2017
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared that sunitinib is unclear.
Purpose The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized, placebo-controlled designed to evaluate the efficacy of adding bevacizumab capecitabine-cisplatin first-line treatment advanced gastric cancer. Patients and Methods received 7.5 mg/kg or placebo followed by cisplatin 80 mg/m 2 on day 1 plus capecitabine 1,000 twice daily for 14 days every 3 weeks. Fluorouracil permitted patients unable take oral medications. Cisplatin given six cycles; were administered...
Gastric cancer is a major gastrointestinal malignancy for which targeted therapies are emerging as treatment options. This study sought to identify the most prevalent molecular targets in gastric and elucidate systematic patterns of exclusivity co-occurrence among these targets, through comprehensive genomic analysis large panel cancers.Using high-resolution single nucleotide polymorphism arrays, copy number alterations were profiled 233 cancers (193 primary tumours, 40 cell lines) 98...
Background/Aims Studies in animals suggest a physiological role for glucagon-like peptide-1-(7–36)-amide (GLP-1) regulating satiety. The of GLP-1 food intake man has, however, not been investigated. Subjects—Sixteen healthy male subjects were examined double blind placebo controlled fashion. Methods effect graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) synthetic human on feelings hunger satiety was tested volunteers. Results Graded infusions resulted dose dependent reduction...
Purpose A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of in patients metastatic renal cell carcinoma. Patients and Methods RECORD-3 used a crossover treatment design. The primary objective assess progression-free survival (PFS) noninferiority compared sunitinib. Secondary end points included combined PFS for each sequence, overall (OS), safety. Results Of 471 enrolled...
Many solid cancers are known to exhibit a high degree of heterogeneity in their deregulation different oncogenic pathways. We sought identify major pathways gastric cancer (GC) with significant relationships patient survival. Using gene expression signatures, we devised an silico strategy map patterns pathway activation 301 primary cancers, the second highest cause global mortality. identified three (proliferation/stem cell, NF-kappaB, and Wnt/beta-catenin) deregulated majority (>70%)...
KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy sotorasib, a G12C inhibitor, previously treated patients with p.G12C–mutated cancer are unknown.
PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings perioperative European phase III studies, the PRODIGY study (ClinicalTrials.gov identifier: NCT01515748 ) investigated whether neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery adjuvant could improve outcomes versus treatment Korean patients with LAGC. PATIENTS AND METHODS Patients 20-75 years of age, Eastern Cooperative...
<h3>Objective</h3> Differences in gastric cancer (GC) clinical outcomes between patients Asian and non-Asian countries has been historically attributed to variability management. However, recent international Phase III trials suggest that even with standardised treatments, GC differ by geography. Here, we investigated gene expression differences GCs, if these molecular might influence outcome. <h3>Design</h3> We compared profiles of 1016 GCs from six three cohorts, using a two-stage...
This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal carcinoma (nccRCC). In addition, survival outcome of nccRCC patients was characterized.Data on 2215 (1963 with clear-cell RCC [ccRCC] and 252 nccRCC) treated first-line VEGF- mTOR-targeted therapies were collected from IMDC. Time treatment failure (TTF) overall (OS) compared groups favorable, intermediate, poor prognoses according IMDC criteriaThe median OS entire...
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
Purpose Obesity is an established risk factor for clear cell renal carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes with metastatic RCC. Methods The impact BMI (high BMI: ≥ 25 kg/m 2 v low < ) overall survival (OS) outcome targeted therapy was 1,975 from International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) external...